Moderna Therapeutics today reported a 94.5% efficacy for its COVID-19 vaccine, which doesn't need to be stored at the same ultra-cold temperatures as does a similar vaccine developed by Pfizer. It also said short-term safety concerns, such as headaches and injection site soreness, self-resolved within days, and that it could have 20 million doses available by year-end.
Axios Re:Cap speaks with Moderna chief medical officer Tal Zaks about the new data, distribution, politics, and how it was preparing for this moment even before COVID-19 was discovered.
President Trump has 10 weeks left in office. In that time, we can expect to see him crack down on China to try to cement his contentious foreign policy legacy.
